Literature DB >> 3276362

The correlation of breakpoint cluster region rearrangement and p210 phl/abl expression with morphological analysis of Ph-negative chronic myeloid leukemia and other myeloproliferative diseases.

L M Wiedemann1, K K Karhi, M K Shivji, S I Rayter, S M Pegram, G Dowden, D Bevan, A Will, D A Galton, L C Chan.   

Abstract

The chromosome 22 derivative, the Philadelphia (Ph) chromosome, results from a reciprocal translocation t(9;22) (q34;q11) and is associated with chronic myeloid leukemia (CML). The translocation can be identified at the DNA level in Ph-positive CML by using a probe to the breakpoint cluster region (bcr). In addition, as a result of this translocation an abl-related 210-kd protein with protein tyrosine kinase (PTK) activity is produced. We analyzed 28 cases of Ph-negative CML for rearrangement of the chromosome 22 sequences and found that eight of the 28 show rearrangement of the bcr. When 12 of the Ph-negative cases were independently reviewed, five were indistinguishable from Ph-positive CML on the basis of morphology, peripheral blood film and clinical details. These five also showed bcr rearrangement. The other seven were reclassified as six atypical CML (aCML) and one chronic myelomonocytic leukemia (CMML). None of these seven showed bcr rearrangement. In addition 11 cases of bcr- CML were assayed for abl-related PTK, and no detectable activity was present, whereas p210 phl/abl PTK was observed both in Ph-positive (three cases examined) and Ph-negative, bcr + (four cases examined) CML. Therefore, bcr + CML, whether or not the Ph chromosome is cytogenetically apparent, involves a similar molecular alteration and produces the 210-kd protein with enhanced PTK activity. Furthermore, these cases can be distinguished from Ph-negative bcr- CML by careful evaluation of clinical and hematologic data.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3276362

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  Haematology.

Authors:  N T O'Connor
Journal:  Postgrad Med J       Date:  1990-08       Impact factor: 2.401

2.  Ph-negative and bcr-negative atypical chronic myelogenous leukemia: biological features and clinical outcome.

Authors:  E Montefusco; G Alimena; F Lo Coco; M R De Cuia; Y Z Wang; M A Aloe Spiriti; F Mancini; M Cedrone; M Mancini; F Mandelli
Journal:  Ann Hematol       Date:  1992-07       Impact factor: 3.673

Review 3.  Molecular analysis of the Philadelphia chromosome.

Authors:  A Dobrovic; G B Peters; J H Ford
Journal:  Chromosoma       Date:  1991-09       Impact factor: 4.316

4.  Is the practice of haematology evidence based? II. Evidence based morphological diagnosis.

Authors:  M M Reid; M J Galloway
Journal:  J Clin Pathol       Date:  1998-06       Impact factor: 3.411

5.  Amplification of BCR protein associated with oncogenesis in human hepatocellular carcinoma.

Authors:  Y Miyazaki; T Mitsuma; T Ichida; H Odazima; K Ishihara; H Asakura
Journal:  Dig Dis Sci       Date:  1997-05       Impact factor: 3.199

Review 6.  Molecular analysis of Philadelphia chromosome positive leukaemias.

Authors:  B D Young
Journal:  Br J Cancer Suppl       Date:  1988-12

7.  Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein.

Authors:  G Q Daley; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

8.  Lymph node disease with lymphocytic abnormal chromatin clumping in a myelodysplastic/myeloproliferative syndrome.

Authors:  J Gardais
Journal:  J Clin Pathol       Date:  1993-02       Impact factor: 3.411

9.  Further evidence for the molecular heterogeneity of chronic myeloid leukemia.

Authors:  A Hernandez; L Corral; A Muñiz; C Alaez; E Espinosa; G Martinez; P Hernandez
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.